Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib vs Capecitabine in Advanced Breast Cancer
NCT00373113Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2006
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of sunitinib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival at 22 months. Started Nov 2006; status: terminated.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00373113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373113.